Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

Mim8 (denecimig) prophylaxis was well-tolerated in FRONTIER5 phase 3 switch trial in people with haemophilia A ·         New FRONTIER5 data shows direct switch to Mim8 prophylaxis treatment from ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...

A patient at Guy’s and St Thomas’ recently received the first treatment in the UK of a new, potentially life-changing ...

The Indian Council of Medical Research's National Institute of Immunohaematology (ICMR's NIIH) has developed a cost-effective ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...

BJP executive member, Raman Suri has expressed concerns over the persistent non-availability of essential medicines for Haemophilia patients in Government Medical Colleges and Hospitals across J&K.

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

Subsequent studies by other investigators confirmed those early results, ultimately leading to the FDA approval of ...